Geron Corporation (GERN)
NMS · Healthcare · Biotechnology
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 47.2M | 48.0M | 51.8M | 57.5M |
| Gross Profit | 46.2M | 46.7M | 50.1M | 48.2M |
| Operating Income | (13.9M) | (8.5M) | (236K) | (12.7M) |
| Net Income | (18.4M) | (28.9M) | (3.6M) | (16.7M) |
| Diluted EPS | $-0.03 | $-0.05 | $-0.01 | $-0.02 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 596K | 237K | 77.0M | 183.9M |
| Gross Profit | 596K | 237K | 75.7M | 179.1M |
| Operating Income | (138.6M) | (193.9M) | (173.7M) | (51.6M) |
| Net Income | (141.9M) | (184.1M) | (174.6M) | (83.5M) |
| Diluted EPS | $-0.37 | $-0.32 | $-0.27 | $-0.13 |